CHENGDU, China, Nov. 17 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., , a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will present at the ROTH Capital Partners Second Annual "China Only" Conference on Friday, November 21st, 2008. The Conference will be held on November 19-21, 2008 at Wynn Hotel in Las Vegas.
The Company's presentation will take place in Palmer 2 - Track 2 at 10:30 a.m. PST. Dr. Guoqing Jiang, Tianyin's Chairman and CEO, Mr. Allen Tang, assistant to the CEO, and Mr. Stewart Lor, a member of the Board of Directors, will be representing Tianyin at the conference and will be available for one- on-one meetings with analysts and investors throughout the day.
Management will discuss the Company's current product portfolio, development pipeline, research and development platform, recent financial highlights and its long-term growth strategy.
Participation is by invitation and registration is mandatory. For more information on the conference, please contact your ROTH representative or visit www.roth.com.
About ROTH Capital Partners
ROTH is a full service investment banking firm dedicated to the small and micro-cap market. The firm is privately owned with current principals being majority owners. The core management team has been consistent for many years. Since the inception of the firm in 1984, ROTH has been a leader and innovator in the small and micro cap markets. ROTH's exclusive focus has been, is, and will continue to offer a full spectrum of investment banking services, including raising capital, research coverage, trading and market making, merger and acquisition advisory services, and investor conferences.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 5 generic Western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 47 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin Pharmaceuticals, please visit http://www.tianyinpharma.com.
Safe Harbor Statement
This Press Release contains or may contain forward looking statements and information that are based upon beliefs of and information currently available to the Company's management as well as estimates and assumptions made by the Company's management. When used herein the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" and similar expressions as they relate to the Company or the Company's management identify forward looking statements. These statements involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, intended or planned.
CONTACT: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO,
China +15821225642, Allen.y.tang@gmail.com; Investors: Alan Sheinwald, HC
International, Inc., US +1-914-669-0222, Alan.Sheinwald@hcinternational.net
Web site: http://www.tianyinpharma.com/
http://www.roth.com/
